Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide Long-Term Extension in CIS (TERICIS)
NCT02587195Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Dec 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teriflunomide in clinically isolated syndrome (CIS) and multiple sclerosis (MS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Adverse event reporting at 6 months and Adverse Events That Are Related to Treatment at 6 months. Started Dec 2015; status: completed.
02
Drugs
teriflunomide
03
Conditions
clinically isolated syndrome (CIS)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02587195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587195.